New Drug Approvals (Original) — May 26, 2026

GALDERMA LABORATORIES, L.P received a label expansion for ADAPALENE, BENZOYL PEROXIDE (DIFFERIN EPIDUO ACNE GEL), which could broaden the addressable patient population and extend the product's commercial lifecycle. This is a positive signal for Galderma's acne franchise, though peak sales and exclusivity details are NOT_DISCLOSED.

MANKIND PHARMA LTD received approval for SITAGLIPTIN, METFORMIN HYDROCHLORIDE, and AUROBINDO PHARMA LIMITED received approval for EMPAGLIFLOZIN. These generic entries could accelerate erosion of originator market share for Merck's Janumet and Boehringer Ingelheim/Eli Lilly's Jardiance, respectively.

Multiple generic approvals for high-volume diabetes drugs (SITAGLIPTIN, METFORMIN HYDROCHLORIDE and EMPAGLIFLOZIN) may lead to rapid price erosion and revenue loss for originators Merck and Boehringer Ingelheim/Eli Lilly. The lack of NME approvals in this period also signals a dearth of innovative catalysts for the sector.

The approval for CLONAZEPAM by RUBICON RESEARCH and LACOSAMIDE by STERANCO HLTHCARE introduces additional generic competition in the CNS space, potentially pressuring pricing for branded antiseizure medications.

GALDERMA LABORATORIES, L.P's label expansion for ADAPALENE, BENZOYL PEROXIDE (DIFFERIN EPIDUO ACNE GEL) could unlock incremental revenue in the acne treatment market, though specific indication and sales estimates are NOT_DISCLOSED.

Generic approvals for LEVOTHYROXINE SODIUM by ALEMBIC and the unknown drug by MSN LABORATORIES PRIVATE LIMITED represent entry opportunities for these sponsors into established markets, though commercial impact is uncertain without sales data.

This period saw approvals for generic versions of key diabetes drugs (SITAGLIPTIN, METFORMIN HYDROCHLORIDE and EMPAGLIFLOZIN) and CNS drugs (CLONAZEPAM and LACOSAMIDE), indicating a continued wave of generic competition in high-volume chronic disease markets.

GALDERMA LABORATORIES, L.P's label expansion for ADAPALENE, BENZOYL PEROXIDE highlights the use of label expansions to extend product lifecycles in dermatology, a strategy that can provide moderate upside without the risk of NME development.

{"entity"=>"MANKIND PHARMA LTD", "reason"=>"Received approval for SITAGLIPTIN, METFORMIN HYDROCHLORIDE, a generic version of Merck's Janumet, which could drive near-term revenue for the sponsor.", "trigger"=>"Product launch date and initial market share data"}

{"entity"=>"AUROBINDO PHARMA LIMITED", "reason"=>"Received approval for EMPAGLIFLOZIN, a generic version of Jardiance, a top-selling diabetes drug; launch timing will be critical for revenue impact.", "trigger"=>"Product launch date and pricing strategy"}

{"entity"=>"GALDERMA LABORATORIES, L.P", "reason"=>"Label expansion for DIFFERIN EPIDUO ACNE GEL could provide incremental growth; monitor physician adoption and payer coverage.", "trigger"=>"Label expansion details and initial prescription trends"}